JP2023506732A5 - - Google Patents
Info
- Publication number
- JP2023506732A5 JP2023506732A5 JP2022535060A JP2022535060A JP2023506732A5 JP 2023506732 A5 JP2023506732 A5 JP 2023506732A5 JP 2022535060 A JP2022535060 A JP 2022535060A JP 2022535060 A JP2022535060 A JP 2022535060A JP 2023506732 A5 JP2023506732 A5 JP 2023506732A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antigen
- binding fragment
- antibody
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962946268P | 2019-12-10 | 2019-12-10 | |
| US62/946,268 | 2019-12-10 | ||
| US202062987148P | 2020-03-09 | 2020-03-09 | |
| US62/987,148 | 2020-03-09 | ||
| PCT/US2020/064324 WO2021119321A1 (en) | 2019-12-10 | 2020-12-10 | Use of a pcsk9 inhibitor to treat homozygous familial hypercholesterolemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023506732A JP2023506732A (ja) | 2023-02-20 |
| JP2023506732A5 true JP2023506732A5 (enExample) | 2023-12-18 |
Family
ID=74175938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022535060A Pending JP2023506732A (ja) | 2019-12-10 | 2020-12-10 | ホモ接合型家族性高コレステロール血症を処置するためのｐｃｓｋ９阻害剤の使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230272112A1 (enExample) |
| EP (1) | EP4072672A1 (enExample) |
| JP (1) | JP2023506732A (enExample) |
| KR (1) | KR20220125249A (enExample) |
| CN (1) | CN115066272A (enExample) |
| AU (1) | AU2020402044A1 (enExample) |
| CA (1) | CA3161347A1 (enExample) |
| IL (1) | IL293617A (enExample) |
| MX (1) | MX2022007071A (enExample) |
| WO (1) | WO2021119321A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202191890A1 (ru) | 2019-01-18 | 2022-02-03 | Астразенека Аб | Ингибиторы pcsk9 и способы их применения |
| US11248001B2 (en) | 2019-01-18 | 2022-02-15 | Astrazeneca Ab | PCSK9 inhibitors and methods of use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| HUE069234T2 (hu) * | 2011-09-16 | 2025-02-28 | Regeneron Pharma | Eljárások lipoprotein(a)-szint csökkentésére proprotein-konvertáz szubtilizin/kexin 9 (PCSK9) inhibitorának beadásával |
| TWI682780B (zh) * | 2013-05-30 | 2020-01-21 | 美商再生元醫藥公司 | 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途 |
| US10111953B2 (en) * | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| US20150004174A1 (en) * | 2013-06-28 | 2015-01-01 | Amgen Inc. | Methods for treating homozygous familial hypercholesterolemia |
| ES2914978T3 (es) * | 2013-10-11 | 2022-06-20 | Sanofi Biotechnology | Uso de un inhibidor de PCSK9 para tratar hiperlipidemia |
| CN107206068A (zh) * | 2014-07-16 | 2017-09-26 | 赛诺菲生物技术公司 | 用于治疗杂合型家族性高胆固醇血症(heFH)患者的方法 |
| PT3689913T (pt) * | 2014-10-09 | 2022-06-20 | Regeneron Pharma | Uso de um inibidor de pcsk9 para tratar a hiperlipidemia |
| CA3014919A1 (en) * | 2016-02-26 | 2017-08-31 | Gemphire Therapeutics Inc. | Treatment of patients with homozygous familial hypercholesterolemia on lipid-lowering therapy |
-
2020
- 2020-12-10 WO PCT/US2020/064324 patent/WO2021119321A1/en not_active Ceased
- 2020-12-10 KR KR1020227023394A patent/KR20220125249A/ko active Pending
- 2020-12-10 JP JP2022535060A patent/JP2023506732A/ja active Pending
- 2020-12-10 MX MX2022007071A patent/MX2022007071A/es unknown
- 2020-12-10 CN CN202080095840.4A patent/CN115066272A/zh active Pending
- 2020-12-10 AU AU2020402044A patent/AU2020402044A1/en active Pending
- 2020-12-10 CA CA3161347A patent/CA3161347A1/en active Pending
- 2020-12-10 EP EP20839171.4A patent/EP4072672A1/en active Pending
- 2020-12-10 US US17/782,930 patent/US20230272112A1/en active Pending
- 2020-12-10 IL IL293617A patent/IL293617A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240261400A1 (en) | Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab | |
| US20230000976A1 (en) | Methods for treating patients with familial hypercholesterolemia | |
| ES2914978T3 (es) | Uso de un inhibidor de PCSK9 para tratar hiperlipidemia | |
| JP2022000443A5 (enExample) | ||
| JP2022133396A5 (enExample) | ||
| IL277127B1 (en) | Using pcsk9 tracking to reduce cardiovascular risk | |
| US20180296672A1 (en) | Methods for Treating Patients with Hypercholesterolemia that is not Adequately Controlled by Moderate-Dose Statin Therapy | |
| JP2016538277A5 (enExample) | ||
| RU2016142277A (ru) | Антитела человека к pcsk9 для применения в способах лечения конкретных групп индивидуумов | |
| JP2017522316A5 (enExample) | ||
| RU2017104799A (ru) | Способы лечения пациентов с высоким риском возникновения сердечно-сосудистых заболеваний, имеющих гиперхолестеринемию | |
| JP2017528427A5 (enExample) | ||
| JP2022078306A (ja) | Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法 | |
| FI3416684T3 (fi) | Menetelmiä ateroskleroosin hoitamiseksi tai ehkäisemiseksi antamalla ANGPTL3:n inhibiittoria | |
| JP2018523684A5 (enExample) | ||
| JP2019512472A5 (enExample) | ||
| US20240197870A1 (en) | Methods for treating patients with refractory hypercholesterolemia | |
| Ilyinskii et al. | Readministration of high-dose adeno-associated virus gene therapy vectors enabled by ImmTOR nanoparticles combined with B cell-targeted agents | |
| Yabuuchi et al. | Long-term low-density lipoprotein apheresis in a patient with refractory idiopathic membranous glomerulonephritis | |
| JP2020143156A (ja) | 心血管リスクを低減させる方法 | |
| ES2779126T3 (es) | Uso de un inhibidor de PCSK9 para tratar hiperlipidemia | |
| EP4122493A1 (en) | Method for treating cholesterol-related diseases | |
| Imai et al. | Real-world outcomes after switching from standard therapy to efgartigimod in five patients with chronic inflammatory demyelinating polyradiculoneuropathy: a case series study in Japan | |
| WO2024130165A1 (en) | Angptl3 inhibitors for triglyceride reduction in multifactorial chylomicronemia syndrome | |
| Eikkula | Developing orally bioavailable PCSK9-inhibitors |